Alkapharmics SARL, is pioneering the development of a novel class of allosteric GPCR modulating small molecules for immune mediated inflammatory diseases. Our compounds, via altered G-Protein signalling, selectively increase production of cyclic adenosine monophosphate (cAMP) in the presence of inflammation. This results in selective regulation of pro- and anti-inflammatory molecules in innate and adaptive immune cells relevant for broad range of immune mediated inflammatory diseases.